Five Days in Hong Kong: The International Congress of Parkinson Disease and Movement Disorders

Conferences|International Parkinson and Movement Disorders Society Congress

You’ll want to get to bed early on Thursday, because you’ll have a very full week ahead. And even if you can't make #MDSCongress, October 5-9, 2018, get your highlights and Editor's Picks here.

Related Videos
Lisanne Dommershuijsen, MSc, PhD candidate in epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands
Lisanne Dommershuijsen, MSc, PhD candidate, Erasmus University Medical Center
Lisanne Dommershuijsen, MSc, PhD candidate, Erasmus University Medical Center
Saar Anis, MD, neurologist and movement disorders specialist at the Sheba Tel-HaShomer Medical Center in Israel
Saar Anis, MD, neurologist and movement disorders specialist, Movement Disorders Institute, neurology department, Sheba Tel-HaShomer Medical Center, Israel
Saar Anis, MD, neurologist and movement disorders specialist, Movement Disorders Institute, neurology department, Sheba Tel-HaShomer Medical Center, Israel
Saar Anis, MD, neurologist and movement disorders specialist, Movement Disorders Institute, neurology department, Sheba Tel-Hashomer Medical Center, Israel
Related Content

Virtual Yoga Program Beneficial for Individuals With Functional Neurological Disorder

October 4th 2022

Migraine Linked to Increased Risk of Parkinson Disease in the Middle-aged and Older Population

September 20th 2022

IncobotulinumtoxinA Supported for the Treatment of Neurological Disorders in Adults

September 19th 2022

Several Genetic Loci Show Increased Risk of Mortality, Cognitive Impairment in Parkinson Disease

September 19th 2022

Selective Adenosine A2A Antagonist KW-6356 Demonstrates Efficacy, Safety as Adjunct to Levodopa in Parkinson Disease

September 18th 2022

Remote Yoga Program Feasible and Benefits Individuals with Functional Neurological Disorder

September 17th 2022

Virtual Yoga Program Beneficial for Individuals With Functional Neurological Disorder

October 4th 2022

Migraine Linked to Increased Risk of Parkinson Disease in the Middle-aged and Older Population

September 20th 2022

IncobotulinumtoxinA Supported for the Treatment of Neurological Disorders in Adults

September 19th 2022

Several Genetic Loci Show Increased Risk of Mortality, Cognitive Impairment in Parkinson Disease

September 19th 2022

Selective Adenosine A2A Antagonist KW-6356 Demonstrates Efficacy, Safety as Adjunct to Levodopa in Parkinson Disease

September 18th 2022

Remote Yoga Program Feasible and Benefits Individuals with Functional Neurological Disorder

September 17th 2022

Virtual Yoga Program Beneficial for Individuals With Functional Neurological Disorder

October 4th 2022

Migraine Linked to Increased Risk of Parkinson Disease in the Middle-aged and Older Population

September 20th 2022

IncobotulinumtoxinA Supported for the Treatment of Neurological Disorders in Adults

September 19th 2022

Several Genetic Loci Show Increased Risk of Mortality, Cognitive Impairment in Parkinson Disease

September 19th 2022

Selective Adenosine A2A Antagonist KW-6356 Demonstrates Efficacy, Safety as Adjunct to Levodopa in Parkinson Disease

September 18th 2022

Remote Yoga Program Feasible and Benefits Individuals with Functional Neurological Disorder

September 17th 2022
© 2023 MJH Life Sciences

All rights reserved.